MetaCap

Insight Molecular Diagnostics (IMDX) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Achieve Life Sciences is the larger company by market cap ($573.2 million vs $80.9 million), about 7.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMDX-53.86%QUIT-25.87%
+18%-25%-67%
Aug 17, 20261 yearNov 20, 2026
IMDX-54.61%QUIT-30.41%
+9%-24%-58%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMDX versus QUIT key metrics
MetricIMDXQUIT
Share price$1.97$5.56
Market cap$80.88M$573.25M
1-day change+18.67%-5.28%
YTD return-73.73%—
1-year return-67.38%—
5-year return-95.91%—
EPS (TTM)$-1.27$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.05M—
Revenue growth (YoY)+115.58%—
Net income (latest FY)$-50.22M$-54.65M
Gross margin56.67%—
Operating margin-1260.76%—
Net margin-1238.52%—
52-week high$7.51$8.64
52-week low$1.50$2.62
Distance from 52-week high-73.77%-35.65%
Analyst consensusbuystrong_buy
Avg. price target upside+318.78%+162.23%
Average volume261.88K1.38M
Shares outstanding41.05M103.10M
Employees5528
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Achieve Life Sciences is about 7.1 times larger than Insight Molecular Diagnostics by market value ($573.25M vs $80.88M).

About Insight Molecular Diagnostics

IMDX stock →

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

IMDX vs QUIT FAQ

Which is bigger, Insight Molecular Diagnostics or Achieve Life Sciences?

Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $80.88M for Insight Molecular Diagnostics (IMDX).

Are Insight Molecular Diagnostics and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons